{"id": "article-131342_0", "title": "Substance Use Disorder (Archived) -- Introduction", "content": "Substance use disorders\u00a0involve\u00a0excessive use of\u00a0nicotine, alcohol,\u00a0and\u00a0other illicit\u00a0substances that leads to social, academic, and occupational impairment. The\u00a0most common\u00a0illicit substances\u00a0seen\u00a0include\u00a0cannabis, sedatives, hypnotics, anxiolytics, inhalants, opioids, hallucinogens, and stimulants. The specific factors of substance use disorder consist of abuse, intoxication,\u00a0and physical/psychological dependence.", "contents": "Substance Use Disorder (Archived) -- Introduction. Substance use disorders\u00a0involve\u00a0excessive use of\u00a0nicotine, alcohol,\u00a0and\u00a0other illicit\u00a0substances that leads to social, academic, and occupational impairment. The\u00a0most common\u00a0illicit substances\u00a0seen\u00a0include\u00a0cannabis, sedatives, hypnotics, anxiolytics, inhalants, opioids, hallucinogens, and stimulants. The specific factors of substance use disorder consist of abuse, intoxication,\u00a0and physical/psychological dependence."}
{"id": "article-131342_1", "title": "Substance Use Disorder (Archived) -- Introduction", "content": "Different\u00a0substances\u00a0can be\u00a0classified based\u00a0on their effects\u00a0on\u00a0the central nervous system.\u00a0These effects vary\u00a0depending\u00a0on the substance and can produce everything from increased\u00a0energy and euphoria to profound\u00a0sedation. In general, while the\u00a0effects vary significantly, the\u00a0initial\u00a0stages\u00a0of substance use disorders are characterized by\u00a0positive\u00a0reinforcement, where individuals experience\u00a0a sense of well-being or euphoria\u00a0with use.\u00a0As physiological and psychological dependence progresses,\u00a0an individual experiences negative reinforcement where substances primarily relieve dysphoria and unpleasant withdrawal symptoms.", "contents": "Substance Use Disorder (Archived) -- Introduction. Different\u00a0substances\u00a0can be\u00a0classified based\u00a0on their effects\u00a0on\u00a0the central nervous system.\u00a0These effects vary\u00a0depending\u00a0on the substance and can produce everything from increased\u00a0energy and euphoria to profound\u00a0sedation. In general, while the\u00a0effects vary significantly, the\u00a0initial\u00a0stages\u00a0of substance use disorders are characterized by\u00a0positive\u00a0reinforcement, where individuals experience\u00a0a sense of well-being or euphoria\u00a0with use.\u00a0As physiological and psychological dependence progresses,\u00a0an individual experiences negative reinforcement where substances primarily relieve dysphoria and unpleasant withdrawal symptoms."}
{"id": "article-131342_2", "title": "Substance Use Disorder (Archived) -- Etiology", "content": "The cause of substance use\u00a0disorders\u00a0is multifactorial\u00a0and\u00a0includes psychological, biological, socio-cultural, and environmental\u00a0factors.\u00a0Co-morbid\u00a0psychiatric disorders\u00a0have been associated with an increased\u00a0risk\u00a0of illicit substance\u00a0use.\u00a0For example, those with attention deficit hyperactivity disorder (ADHD) and bipolar affective disorders\u00a0have\u00a0an increased risk of developing a substance use disorder in adulthood\u00a0compared to the general population.", "contents": "Substance Use Disorder (Archived) -- Etiology. The cause of substance use\u00a0disorders\u00a0is multifactorial\u00a0and\u00a0includes psychological, biological, socio-cultural, and environmental\u00a0factors.\u00a0Co-morbid\u00a0psychiatric disorders\u00a0have been associated with an increased\u00a0risk\u00a0of illicit substance\u00a0use.\u00a0For example, those with attention deficit hyperactivity disorder (ADHD) and bipolar affective disorders\u00a0have\u00a0an increased risk of developing a substance use disorder in adulthood\u00a0compared to the general population."}
{"id": "article-131342_3", "title": "Substance Use Disorder (Archived) -- Etiology", "content": "Environmental and genetic factors also play a strong role in substance use disorder.\u00a0An\u00a0individual's genetic\u00a0make-up for\u00a0stress-response\u00a0predisposes\u00a0the\u00a0risk of dependence on substances. Individual variations in genetics\u00a0have been\u00a0demonstrated\u00a0to influence stress response and predispose some individuals to develop a substance use disorder. [1]", "contents": "Substance Use Disorder (Archived) -- Etiology. Environmental and genetic factors also play a strong role in substance use disorder.\u00a0An\u00a0individual's genetic\u00a0make-up for\u00a0stress-response\u00a0predisposes\u00a0the\u00a0risk of dependence on substances. Individual variations in genetics\u00a0have been\u00a0demonstrated\u00a0to influence stress response and predispose some individuals to develop a substance use disorder. [1]"}
{"id": "article-131342_4", "title": "Substance Use Disorder (Archived) -- Etiology", "content": "The Adverse Childhood Experience Study (ACES)\u00a0demonstrated\u00a0that exposure to a range of traumatic events during childhood\u00a0is associated with an increased risk of substance use later in life. This risk association was\u00a0demonstrated\u00a0to follow a dose-response-like pattern where increased trauma exposure was directly correlated with increased risk of developing a substance use disorder.", "contents": "Substance Use Disorder (Archived) -- Etiology. The Adverse Childhood Experience Study (ACES)\u00a0demonstrated\u00a0that exposure to a range of traumatic events during childhood\u00a0is associated with an increased risk of substance use later in life. This risk association was\u00a0demonstrated\u00a0to follow a dose-response-like pattern where increased trauma exposure was directly correlated with increased risk of developing a substance use disorder."}
{"id": "article-131342_5", "title": "Substance Use Disorder (Archived) -- Epidemiology", "content": "The cause of substance use is multifactorial. It includes psychological, biological, socio-cultural, and environmental factors. Some mental health disorders predispose individuals to abuse illicit substances; for example, those with ADHD have a high chance of abusing illicit substances in their\u00a0adulthood. [1] Cannabis is the most common abused drug in the United States. [2]", "contents": "Substance Use Disorder (Archived) -- Epidemiology. The cause of substance use is multifactorial. It includes psychological, biological, socio-cultural, and environmental factors. Some mental health disorders predispose individuals to abuse illicit substances; for example, those with ADHD have a high chance of abusing illicit substances in their\u00a0adulthood. [1] Cannabis is the most common abused drug in the United States. [2]"}
{"id": "article-131342_6", "title": "Substance Use Disorder (Archived) -- Epidemiology", "content": "The Services Administration for Mental Health and Substance Abuse (SAHMSA), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the National Institute of Drug Abuse (NIDA)\u00a0have\u00a0accumulated\u00a0data on\u00a0substance use and its consequences over the years. Studies show individuals who abuse one substance are more like to abuse other substances as well. In 2012, studies showed that the lifetime prevalence of alcohol use disorder was 8%, and illicit substance use was 2-3%. [3]", "contents": "Substance Use Disorder (Archived) -- Epidemiology. The Services Administration for Mental Health and Substance Abuse (SAHMSA), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the National Institute of Drug Abuse (NIDA)\u00a0have\u00a0accumulated\u00a0data on\u00a0substance use and its consequences over the years. Studies show individuals who abuse one substance are more like to abuse other substances as well. In 2012, studies showed that the lifetime prevalence of alcohol use disorder was 8%, and illicit substance use was 2-3%. [3]"}
{"id": "article-131342_7", "title": "Substance Use Disorder (Archived) -- Epidemiology", "content": "A cross-sectional study was conducted\u00a0in the US\u00a0with 36,309 adults,\u00a0and\u00a0the\u00a0data was obtained from April 2012 to June 2013.\u00a0The study showed a 12-month prevalence of substance use disorder was 3.9% and lifetime substance use disorder was 9.9%.\u00a0Substance use disorder was more prominent among\u00a0certain population groups. They were\u00a0men, Caucasian,\u00a0Native Americans, young single or previously married adults, lower educated individuals, lower-income individuals, and those\u00a0residing\u00a0on the Western side of the country. There was a significant association\u00a0with individuals with disabilities,\u00a0with a\u00a012-month\u00a0prevalence\u00a0of 13.5% and a lifetime prevalence of 24.6%. [4]", "contents": "Substance Use Disorder (Archived) -- Epidemiology. A cross-sectional study was conducted\u00a0in the US\u00a0with 36,309 adults,\u00a0and\u00a0the\u00a0data was obtained from April 2012 to June 2013.\u00a0The study showed a 12-month prevalence of substance use disorder was 3.9% and lifetime substance use disorder was 9.9%.\u00a0Substance use disorder was more prominent among\u00a0certain population groups. They were\u00a0men, Caucasian,\u00a0Native Americans, young single or previously married adults, lower educated individuals, lower-income individuals, and those\u00a0residing\u00a0on the Western side of the country. There was a significant association\u00a0with individuals with disabilities,\u00a0with a\u00a012-month\u00a0prevalence\u00a0of 13.5% and a lifetime prevalence of 24.6%. [4]"}
{"id": "article-131342_8", "title": "Substance Use Disorder (Archived) -- Pathophysiology", "content": "Substance use disorders\u00a0involve\u00a0both psychological\u00a0and physical dependence on the substance(s) of use.\u00a0Severe dependence\u00a0is characterized by an\u00a0inability to\u00a0regulate use. Substance use disorders\u00a0and addiction\u00a0stem in part from\u00a0adaptive\u00a0changes in the brain as it\u00a0seeks\u00a0to regain\u00a0homeostasis. [5] Chronic and/or prolonged stress plays a strong role in developing drug-seeking behavior; it alters the corticotropin-releasing factor and hypothalamic-pituitary-adrenal axis (CRF/HPA)\". In animal model studies, it demonstrated CRF circuitry could increase \"dopamine activity in the mesolimbic reward circuit.\" [6]", "contents": "Substance Use Disorder (Archived) -- Pathophysiology. Substance use disorders\u00a0involve\u00a0both psychological\u00a0and physical dependence on the substance(s) of use.\u00a0Severe dependence\u00a0is characterized by an\u00a0inability to\u00a0regulate use. Substance use disorders\u00a0and addiction\u00a0stem in part from\u00a0adaptive\u00a0changes in the brain as it\u00a0seeks\u00a0to regain\u00a0homeostasis. [5] Chronic and/or prolonged stress plays a strong role in developing drug-seeking behavior; it alters the corticotropin-releasing factor and hypothalamic-pituitary-adrenal axis (CRF/HPA)\". In animal model studies, it demonstrated CRF circuitry could increase \"dopamine activity in the mesolimbic reward circuit.\" [6]"}
{"id": "article-131342_9", "title": "Substance Use Disorder (Archived) -- Pathophysiology", "content": "Stimulants,\u00a0specifically\u00a0cocaine and amphetamines,\u00a0exert their effect\u00a0by\u00a0preventing the recycling of\u00a0dopamine,\u00a0norepinephrine,\u00a0and serotonin.\u00a0\u00a0This results in\u00a0increased\u00a0concentrations\u00a0of\u00a0these\u00a0neurotransmitters within the synaptic\u00a0cleft. The\u00a0influx of these neurotransmitters gives the user a euphoric effect. [7]", "contents": "Substance Use Disorder (Archived) -- Pathophysiology. Stimulants,\u00a0specifically\u00a0cocaine and amphetamines,\u00a0exert their effect\u00a0by\u00a0preventing the recycling of\u00a0dopamine,\u00a0norepinephrine,\u00a0and serotonin.\u00a0\u00a0This results in\u00a0increased\u00a0concentrations\u00a0of\u00a0these\u00a0neurotransmitters within the synaptic\u00a0cleft. The\u00a0influx of these neurotransmitters gives the user a euphoric effect. [7]"}
{"id": "article-131342_10", "title": "Substance Use Disorder (Archived) -- Pathophysiology", "content": "Worldwide and in the United States, tobacco use disorder is the most prevalent addiction.\u00a0\u00a0Most commonly,\u00a0nicotine\u00a0is\u00a0absorbed through the\u00a0lungs\u00a0when individuals burn and inhale tobacco products.\u00a0It is\u00a0absorbed\u00a0through\u00a0the pulmonary circulation,\u00a0crosses the blood-brain barrier in less than 10 seconds,\u00a0and attaches to the nicotinic cholinergic receptors\u00a0in the central nervous system\u00a0(CNS).\u00a0The metabolite of nicotine is\u00a0cotinine, which can be detected as a urinary marker of the substance. [8] Nicotine influx in\u00a0the CNS\u00a0leads\u00a0to neurotransmitters' release, especially\u00a0dopamine,\u00a0which\u00a0stimulates the brain\u2019s reward\u00a0area.\u00a0Chronic nicotine use\u00a0results in\u00a0tolerance,\u00a0when\u00a0excessive stimulation of\u00a0nicotine acetylcholine\u00a0receptors results\u00a0in\u00a0desensitization of the\u00a0receptors; these\u00a0neuroadaptations\u00a0produce\u00a0a state where the brain\u00a0requires\u00a0nicotine\u00a0to function in homeostasis.\u00a0This is referred to as physiological dependence. [9] CYP2D6 metabolizes nicotine. Therefore, it can alter the metabolism of other medications, such as antipsychotics.", "contents": "Substance Use Disorder (Archived) -- Pathophysiology. Worldwide and in the United States, tobacco use disorder is the most prevalent addiction.\u00a0\u00a0Most commonly,\u00a0nicotine\u00a0is\u00a0absorbed through the\u00a0lungs\u00a0when individuals burn and inhale tobacco products.\u00a0It is\u00a0absorbed\u00a0through\u00a0the pulmonary circulation,\u00a0crosses the blood-brain barrier in less than 10 seconds,\u00a0and attaches to the nicotinic cholinergic receptors\u00a0in the central nervous system\u00a0(CNS).\u00a0The metabolite of nicotine is\u00a0cotinine, which can be detected as a urinary marker of the substance. [8] Nicotine influx in\u00a0the CNS\u00a0leads\u00a0to neurotransmitters' release, especially\u00a0dopamine,\u00a0which\u00a0stimulates the brain\u2019s reward\u00a0area.\u00a0Chronic nicotine use\u00a0results in\u00a0tolerance,\u00a0when\u00a0excessive stimulation of\u00a0nicotine acetylcholine\u00a0receptors results\u00a0in\u00a0desensitization of the\u00a0receptors; these\u00a0neuroadaptations\u00a0produce\u00a0a state where the brain\u00a0requires\u00a0nicotine\u00a0to function in homeostasis.\u00a0This is referred to as physiological dependence. [9] CYP2D6 metabolizes nicotine. Therefore, it can alter the metabolism of other medications, such as antipsychotics."}
{"id": "article-131342_11", "title": "Substance Use Disorder (Archived) -- Pathophysiology", "content": "Alcohol\u00a0produces euphoric\u00a0effects\u00a0through the\u00a0dopamine neurons\u00a0of\u00a0the mesolimbic system. Alcohol\u00a0inhibits\u00a0NMDA receptors\u00a0and results in the\u00a0upregulation of\u00a0GABA receptors.\u00a0Chronic\u00a0consumption\u00a0of alcohol\u00a0leads\u00a0to\u00a0GABA receptor desensitization\u00a0and tolerance,\u00a0potentiating the loss of drinking control. [10] Alcohol is mostly absorbed in the digestive tract's mucosal lining, specifically at the proximal small intestine, where B vitamins are absorbed. Individuals who\u00a0drink excessively\u00a0may\u00a0have a deficiency of B vitamins. [11] Vitamin B1 (Thiamine) and vitamin B9 (Folic Acid) are the two most common B-vitamins\u00a0deficiencies. Deficiency\u00a0of thiamine\u00a0can\u00a0lead to neurological\u00a0findings such\u00a0as hyporeflexia\u00a0and\u00a0sensory and motor deficiency. More profound deficiencies over time can\u00a0lead to Wernicke's Encephalopathy and Korsakoff syndrome [12] . Chronic alcohol consumption can also\u00a0result in\u00a0Vitamin B9 (Folic acid) deficiency; after 8-16 weeks\u00a0of deficient stores of folic acid in the body,\u00a0individuals\u00a0may develop\u00a0\"glossitis, angular stomatitis, and oral ulcers,\" along with \"depression, irritability, insomnia, cognitive decline, fatigue, and psychosis.\" [13]", "contents": "Substance Use Disorder (Archived) -- Pathophysiology. Alcohol\u00a0produces euphoric\u00a0effects\u00a0through the\u00a0dopamine neurons\u00a0of\u00a0the mesolimbic system. Alcohol\u00a0inhibits\u00a0NMDA receptors\u00a0and results in the\u00a0upregulation of\u00a0GABA receptors.\u00a0Chronic\u00a0consumption\u00a0of alcohol\u00a0leads\u00a0to\u00a0GABA receptor desensitization\u00a0and tolerance,\u00a0potentiating the loss of drinking control. [10] Alcohol is mostly absorbed in the digestive tract's mucosal lining, specifically at the proximal small intestine, where B vitamins are absorbed. Individuals who\u00a0drink excessively\u00a0may\u00a0have a deficiency of B vitamins. [11] Vitamin B1 (Thiamine) and vitamin B9 (Folic Acid) are the two most common B-vitamins\u00a0deficiencies. Deficiency\u00a0of thiamine\u00a0can\u00a0lead to neurological\u00a0findings such\u00a0as hyporeflexia\u00a0and\u00a0sensory and motor deficiency. More profound deficiencies over time can\u00a0lead to Wernicke's Encephalopathy and Korsakoff syndrome [12] . Chronic alcohol consumption can also\u00a0result in\u00a0Vitamin B9 (Folic acid) deficiency; after 8-16 weeks\u00a0of deficient stores of folic acid in the body,\u00a0individuals\u00a0may develop\u00a0\"glossitis, angular stomatitis, and oral ulcers,\" along with \"depression, irritability, insomnia, cognitive decline, fatigue, and psychosis.\" [13]"}
{"id": "article-131342_12", "title": "Substance Use Disorder (Archived) -- Pathophysiology", "content": "Opioids\u00a0include\u00a0codeine,\u00a0heroin,\u00a0hydrocodone,\u00a0hydromorphone,\u00a0methadone,\u00a0meperidine,\u00a0morphine,\u00a0and\u00a0oxycodone.\u00a0Opioids\u00a0bind\u00a0to delta, kappa, and mu receptors, which\u00a0provide\u00a0analgesia for severe pain and produce euphoria feelings. Higher doses carry a risk of respiratory suppression and death.\u00a0Individuals with chronic exposure to opioids can experience\u00a0profound\u00a0withdrawal symptoms if opioid use is stopped abruptly. The withdrawal symptoms\u00a0include\u00a0but\u00a0are\u00a0not limited\u00a0to diarrhea, excess sweating, excess lacrimation, nausea, vomiting,\u00a0and\u00a0insomnia. [14]", "contents": "Substance Use Disorder (Archived) -- Pathophysiology. Opioids\u00a0include\u00a0codeine,\u00a0heroin,\u00a0hydrocodone,\u00a0hydromorphone,\u00a0methadone,\u00a0meperidine,\u00a0morphine,\u00a0and\u00a0oxycodone.\u00a0Opioids\u00a0bind\u00a0to delta, kappa, and mu receptors, which\u00a0provide\u00a0analgesia for severe pain and produce euphoria feelings. Higher doses carry a risk of respiratory suppression and death.\u00a0Individuals with chronic exposure to opioids can experience\u00a0profound\u00a0withdrawal symptoms if opioid use is stopped abruptly. The withdrawal symptoms\u00a0include\u00a0but\u00a0are\u00a0not limited\u00a0to diarrhea, excess sweating, excess lacrimation, nausea, vomiting,\u00a0and\u00a0insomnia. [14]"}
{"id": "article-131342_13", "title": "Substance Use Disorder (Archived) -- Pathophysiology", "content": "Sedative, Hypnotic, Anxiolytics\u00a0are\u00a0a\u00a0class of medications that can cause CNS depression, and if taken inappropriately, the effects can be fatal. They include\u00a0benzodiazepines:\u00a0alprazolam, clonazepam,\u00a0lorazepam, diazepam,\u00a0chlordiazepoxide; Barbiturates:\u00a0\u00a0phenobarbital, pentobarbital,\u00a0butabarbital; it also includes other sedative medications.\u00a0Other\u00a0classes of drugs\u00a0have\u00a0properties\u00a0that\u00a0share a similar mechanism\u00a0of action\u00a0with benzodiazepine and barbiturates.\u00a0These agents\u00a0mediate gamma-aminobutyric\u00a0acid (GABA) effects, producing inhibitory effects within\u00a0the central nervous system.\u00a0Alcohol can be classified in this group, but alcohol is more commonly used\u00a0and\u00a0is not utilized therapeutically, so\u00a0healthcare experts have classified it\u00a0separately. [15] The euphoric and sedative effects of these agents\u00a0precipitate\u00a0and perpetuate\u00a0a cycle of\u00a0overuse\u00a0and\u00a0dependence.", "contents": "Substance Use Disorder (Archived) -- Pathophysiology. Sedative, Hypnotic, Anxiolytics\u00a0are\u00a0a\u00a0class of medications that can cause CNS depression, and if taken inappropriately, the effects can be fatal. They include\u00a0benzodiazepines:\u00a0alprazolam, clonazepam,\u00a0lorazepam, diazepam,\u00a0chlordiazepoxide; Barbiturates:\u00a0\u00a0phenobarbital, pentobarbital,\u00a0butabarbital; it also includes other sedative medications.\u00a0Other\u00a0classes of drugs\u00a0have\u00a0properties\u00a0that\u00a0share a similar mechanism\u00a0of action\u00a0with benzodiazepine and barbiturates.\u00a0These agents\u00a0mediate gamma-aminobutyric\u00a0acid (GABA) effects, producing inhibitory effects within\u00a0the central nervous system.\u00a0Alcohol can be classified in this group, but alcohol is more commonly used\u00a0and\u00a0is not utilized therapeutically, so\u00a0healthcare experts have classified it\u00a0separately. [15] The euphoric and sedative effects of these agents\u00a0precipitate\u00a0and perpetuate\u00a0a cycle of\u00a0overuse\u00a0and\u00a0dependence."}
{"id": "article-131342_14", "title": "Substance Use Disorder (Archived) -- Pathophysiology", "content": "Regarding\u00a0cannabis, it\u00a0contains\u00a0multiple types of\u00a0terpenophenolic\u00a0compounds,\u00a0called\u00a0cannabinoids,\u00a0that cross the blood-brain barrier;\u00a0the most studied cannabinoids\u00a0are\u00a0cannabidiol\u00a0(CBD) and\u00a0tetrahydrocannabinol (THC).\u00a0Cannabinoids act on the cannabinoid receptors, which\u00a0are located in\u00a0the central and peripheral nervous system.\u00a0CBD and THC both come from the hemp plant, also known as marijuana; legal rules and regulations differentiate the definitions.\u00a0There are many types of hemp plants\u00a0that produce\u00a0various\u00a0percentages of THC and CBD.\u00a0Hemp has less than or equal to 0.3% of THC\u00a0by dry weight,\u00a0while marijuana\u00a0has more than 0.3 % of THC\u00a0by dry weight.\u00a0CBD is a\u00a0non-psychotropic cannabinoid\u00a0that does not exert euphoric properties\u00a0like\u00a0THC. [16] THC, the psychoactive cannabinoid,\u00a0exerts its effects in the brain\u2019s reward center in increasing dopamine levels in the prefrontal cortex,\u00a0providing\u00a0the euphoric effect. [2] THC activates the CB1 and CB2 receptors\u00a0of the endocannabinoid system, which gives\u00a0its\u00a0psychoactive properties\u00a0and\u00a0regulating eating, learning, memory, growth, development, and anxiety. [17] CBD\u00a0does not activate CB1 or CB2 receptors,\u00a0but limited studies show it has neuroprotective and anti-inflammatory effects. [18]", "contents": "Substance Use Disorder (Archived) -- Pathophysiology. Regarding\u00a0cannabis, it\u00a0contains\u00a0multiple types of\u00a0terpenophenolic\u00a0compounds,\u00a0called\u00a0cannabinoids,\u00a0that cross the blood-brain barrier;\u00a0the most studied cannabinoids\u00a0are\u00a0cannabidiol\u00a0(CBD) and\u00a0tetrahydrocannabinol (THC).\u00a0Cannabinoids act on the cannabinoid receptors, which\u00a0are located in\u00a0the central and peripheral nervous system.\u00a0CBD and THC both come from the hemp plant, also known as marijuana; legal rules and regulations differentiate the definitions.\u00a0There are many types of hemp plants\u00a0that produce\u00a0various\u00a0percentages of THC and CBD.\u00a0Hemp has less than or equal to 0.3% of THC\u00a0by dry weight,\u00a0while marijuana\u00a0has more than 0.3 % of THC\u00a0by dry weight.\u00a0CBD is a\u00a0non-psychotropic cannabinoid\u00a0that does not exert euphoric properties\u00a0like\u00a0THC. [16] THC, the psychoactive cannabinoid,\u00a0exerts its effects in the brain\u2019s reward center in increasing dopamine levels in the prefrontal cortex,\u00a0providing\u00a0the euphoric effect. [2] THC activates the CB1 and CB2 receptors\u00a0of the endocannabinoid system, which gives\u00a0its\u00a0psychoactive properties\u00a0and\u00a0regulating eating, learning, memory, growth, development, and anxiety. [17] CBD\u00a0does not activate CB1 or CB2 receptors,\u00a0but limited studies show it has neuroprotective and anti-inflammatory effects. [18]"}
{"id": "article-131342_15", "title": "Substance Use Disorder (Archived) -- Pathophysiology", "content": "There\u00a0are\u00a0various hallucinogens; the most common one\u00a0presented in the hospitals is phencyclidine or\u00a0phenylcyclohexyl\u00a0piperidine (PCP), or also known by its street name \"angel\u00a0dust,\"\u00a0is not only a hallucinogen but also acts as a stimulant.\u00a0Its mechanism of action is characterized by NMDA receptor antagonism impairing the feeling of pain and other various neurological functions and psychosis. It can also\u00a0facilitate\u00a0the increase of dopamine and norepinephrine\u00a0and\u00a0provide\u00a0a sympathomimetic effect. [19] Another common hallucinogen is\u00a0Lysergic acid diethylamide (LSD), or known by its street name as \"acid\"; it\u00a0has a mechanism of action that\u00a0is not fully understood,\u00a0but from studies so far, it\u00a0facilitates\u00a0serotonin receptors\u00a05HT2A,\u00a05HTAR, 5HT2C, and 5HT1A.\u00a0LSD exerts\u00a0receptor modulation leading to cognitive impairment and hallucinations.\u00a0Other hallucinogens include MDMA with street names of\u00a0\u201cMolly, Ecstasy, X,\u201d\u00a0another\u00a0hallucinogen is\u00a0Ketamine\u00a0with a street name of \u201cK-Hole.\u201d", "contents": "Substance Use Disorder (Archived) -- Pathophysiology. There\u00a0are\u00a0various hallucinogens; the most common one\u00a0presented in the hospitals is phencyclidine or\u00a0phenylcyclohexyl\u00a0piperidine (PCP), or also known by its street name \"angel\u00a0dust,\"\u00a0is not only a hallucinogen but also acts as a stimulant.\u00a0Its mechanism of action is characterized by NMDA receptor antagonism impairing the feeling of pain and other various neurological functions and psychosis. It can also\u00a0facilitate\u00a0the increase of dopamine and norepinephrine\u00a0and\u00a0provide\u00a0a sympathomimetic effect. [19] Another common hallucinogen is\u00a0Lysergic acid diethylamide (LSD), or known by its street name as \"acid\"; it\u00a0has a mechanism of action that\u00a0is not fully understood,\u00a0but from studies so far, it\u00a0facilitates\u00a0serotonin receptors\u00a05HT2A,\u00a05HTAR, 5HT2C, and 5HT1A.\u00a0LSD exerts\u00a0receptor modulation leading to cognitive impairment and hallucinations.\u00a0Other hallucinogens include MDMA with street names of\u00a0\u201cMolly, Ecstasy, X,\u201d\u00a0another\u00a0hallucinogen is\u00a0Ketamine\u00a0with a street name of \u201cK-Hole.\u201d"}
{"id": "article-131342_16", "title": "Substance Use Disorder (Archived) -- History and Physical", "content": "In addition to the physical exam,\u00a0assessment of substance use\u00a0should include a thorough history\u00a0that\u00a0screens several psychiatric\u00a0symptoms to diagnose and rule out disorders. The patient should be asked about any current life stressors, and the patient should be screened for\u00a0current\u00a0depression, mania, trauma,\u00a0anxiety,\u00a0and psychosis. Current substance use screening questions include:", "contents": "Substance Use Disorder (Archived) -- History and Physical. In addition to the physical exam,\u00a0assessment of substance use\u00a0should include a thorough history\u00a0that\u00a0screens several psychiatric\u00a0symptoms to diagnose and rule out disorders. The patient should be asked about any current life stressors, and the patient should be screened for\u00a0current\u00a0depression, mania, trauma,\u00a0anxiety,\u00a0and psychosis. Current substance use screening questions include:"}
{"id": "article-131342_17", "title": "Substance Use Disorder (Archived) -- History and Physical", "content": "Which substance(s) are used? Certain substances can cause more negatives effects than others, so\u00a0it is\u00a0important to determine which ones were used, which may help in the recovery process.", "contents": "Substance Use Disorder (Archived) -- History and Physical. Which substance(s) are used? Certain substances can cause more negatives effects than others, so\u00a0it is\u00a0important to determine which ones were used, which may help in the recovery process."}
{"id": "article-131342_18", "title": "Substance Use Disorder (Archived) -- History and Physical", "content": "When was the last time the substance was used, and how much and how often was it used? The negative consequences of withdrawal symptoms may be fatal, such as from benzodiazepines or alcohol. If the provider was notified of the last use, then\u00a0appropriate treatment\u00a0can be administered on time. Also, recent substance use can influence an individual\u2019s behavior and cognitive processes, such as being agitated from Methamphetamine or Cocaine. This would help in the treatment process. For example, a patient may not need inpatient admission if the exhibited psychotic symptoms were substance-induced instead of a psychotic episode of Schizophrenia. The frequency of substance use helps\u00a0determine\u00a0the severity of the dependency.", "contents": "Substance Use Disorder (Archived) -- History and Physical. When was the last time the substance was used, and how much and how often was it used? The negative consequences of withdrawal symptoms may be fatal, such as from benzodiazepines or alcohol. If the provider was notified of the last use, then\u00a0appropriate treatment\u00a0can be administered on time. Also, recent substance use can influence an individual\u2019s behavior and cognitive processes, such as being agitated from Methamphetamine or Cocaine. This would help in the treatment process. For example, a patient may not need inpatient admission if the exhibited psychotic symptoms were substance-induced instead of a psychotic episode of Schizophrenia. The frequency of substance use helps\u00a0determine\u00a0the severity of the dependency."}
{"id": "article-131342_19", "title": "Substance Use Disorder (Archived) -- History and Physical", "content": "Any experience of withdrawal symptoms? Some substance use can lead to severe withdrawal symptoms. Alcohol and Benzodiazepine withdrawal can lead to seizures and have the potential to be fatal.", "contents": "Substance Use Disorder (Archived) -- History and Physical. Any experience of withdrawal symptoms? Some substance use can lead to severe withdrawal symptoms. Alcohol and Benzodiazepine withdrawal can lead to seizures and have the potential to be fatal."}
{"id": "article-131342_20", "title": "Substance Use Disorder (Archived) -- History and Physical", "content": "What is the user\u2019s perception of using the substance(s)? How an individual perceives illicit substances will vary from person to person.\u00a0Some individuals\u00a0use substances to cope with life stressors, while others\u00a0may use it as an alternative to medications such as\u00a0cannabis\u00a0for treating their anxiety.", "contents": "Substance Use Disorder (Archived) -- History and Physical. What is the user\u2019s perception of using the substance(s)? How an individual perceives illicit substances will vary from person to person.\u00a0Some individuals\u00a0use substances to cope with life stressors, while others\u00a0may use it as an alternative to medications such as\u00a0cannabis\u00a0for treating their anxiety."}
{"id": "article-131342_21", "title": "Substance Use Disorder (Archived) -- History and Physical", "content": "Any feelings or readiness to change, such as cutting back use or quitting? Does the patient have any cravings for the substance?", "contents": "Substance Use Disorder (Archived) -- History and Physical. Any feelings or readiness to change, such as cutting back use or quitting? Does the patient have any cravings for the substance?"}
{"id": "article-131342_22", "title": "Substance Use Disorder (Archived) -- History and Physical", "content": "Past Psychiatric History:\u00a0if the patient has any psychiatric history,\u00a0detailed\u00a0information\u00a0regarding\u00a0mental health\u00a0history\u00a0should be obtained.\u00a0When asking about\u00a0a period\u00a0in the past,\u00a0it is\u00a0easier to have the patient recall an event by age than recall the year. The questions to ask include:", "contents": "Substance Use Disorder (Archived) -- History and Physical. Past Psychiatric History:\u00a0if the patient has any psychiatric history,\u00a0detailed\u00a0information\u00a0regarding\u00a0mental health\u00a0history\u00a0should be obtained.\u00a0When asking about\u00a0a period\u00a0in the past,\u00a0it is\u00a0easier to have the patient recall an event by age than recall the year. The questions to ask include:"}
{"id": "article-131342_23", "title": "Substance Use Disorder (Archived) -- History and Physical", "content": "Have you been diagnosed with any psychiatric diagnosis in the past by a physician? This question should be asked, and it should be verified if the diagnosis was made by a medical professional or if someone else told them the diagnosis.", "contents": "Substance Use Disorder (Archived) -- History and Physical. Have you been diagnosed with any psychiatric diagnosis in the past by a physician? This question should be asked, and it should be verified if the diagnosis was made by a medical professional or if someone else told them the diagnosis."}
{"id": "article-131342_24", "title": "Substance Use Disorder (Archived) -- History and Physical", "content": "Any history of medication trials for substance use or other mental health disorder? This open-ended question may not have a complete answer because the patient may have\u00a0difficulty\u00a0recalling the complicated names of medications from the past. If the patient affirms taking medications but cannot recall the name, an effective way\u00a0to get the information is to call the\u00a0pharmacy to get the list or get the medical records from their last prescriber.", "contents": "Substance Use Disorder (Archived) -- History and Physical. Any history of medication trials for substance use or other mental health disorder? This open-ended question may not have a complete answer because the patient may have\u00a0difficulty\u00a0recalling the complicated names of medications from the past. If the patient affirms taking medications but cannot recall the name, an effective way\u00a0to get the information is to call the\u00a0pharmacy to get the list or get the medical records from their last prescriber."}
{"id": "article-131342_25", "title": "Substance Use Disorder (Archived) -- History and Physical", "content": "Any history of self-harm or attempted suicide? Perceptual disturbance during an intoxicated state may lead\u00a0to hallucinations, such as having bugs or snakes on their skin. The visual hallucinations may lead to self-harm\u00a0to\u00a0rid self of the hallucinations. Also, auditory hallucinations of commanding nature\u00a0may result in a\u00a0suicide\u00a0attempt. If past suicide attempts are\u00a0identified, then\u00a0it is\u00a0recommended to ask when the first attempt was, how many were\u00a0attempted, and what lead to the suicide attempts,", "contents": "Substance Use Disorder (Archived) -- History and Physical. Any history of self-harm or attempted suicide? Perceptual disturbance during an intoxicated state may lead\u00a0to hallucinations, such as having bugs or snakes on their skin. The visual hallucinations may lead to self-harm\u00a0to\u00a0rid self of the hallucinations. Also, auditory hallucinations of commanding nature\u00a0may result in a\u00a0suicide\u00a0attempt. If past suicide attempts are\u00a0identified, then\u00a0it is\u00a0recommended to ask when the first attempt was, how many were\u00a0attempted, and what lead to the suicide attempts,"}
{"id": "article-131342_26", "title": "Substance Use Disorder (Archived) -- History and Physical", "content": "Any history of violence towards others? A study\u00a0regarding\u00a0ED visits due to Cocaine-induced chest pain found 40% of the patients were involved in violence a year after discharge from the ED. [20] Substance abuse can cause loss of impulse control and agitation, in which the user will have mood dysregulation leading to violent behavior. Obtaining history about the patient\u2019s history of violence enables the provider to assess for any future risks.", "contents": "Substance Use Disorder (Archived) -- History and Physical. Any history of violence towards others? A study\u00a0regarding\u00a0ED visits due to Cocaine-induced chest pain found 40% of the patients were involved in violence a year after discharge from the ED. [20] Substance abuse can cause loss of impulse control and agitation, in which the user will have mood dysregulation leading to violent behavior. Obtaining history about the patient\u2019s history of violence enables the provider to assess for any future risks."}
{"id": "article-131342_27", "title": "Substance Use Disorder (Archived) -- History and Physical", "content": "At what age were the first and last psychiatric hospitalization ? How many hospitalizations regarding substance use or other mental health illness can you recall? These questions should be asked in more detail and asked about the differences of being treated in the ED, such as for\u00a0psychiatric stability or due to intoxication, and if the patient was admitted to inpatient for stabilization. Those who are treated in the ED due to intoxication usually are stabilized and discharged after a day. But those admitted to the inpatient for psychiatric care are admitted for at least 5 days or so until they are\u00a0psychiatrically\u00a0stabilized.", "contents": "Substance Use Disorder (Archived) -- History and Physical. At what age were the first and last psychiatric hospitalization ? How many hospitalizations regarding substance use or other mental health illness can you recall? These questions should be asked in more detail and asked about the differences of being treated in the ED, such as for\u00a0psychiatric stability or due to intoxication, and if the patient was admitted to inpatient for stabilization. Those who are treated in the ED due to intoxication usually are stabilized and discharged after a day. But those admitted to the inpatient for psychiatric care are admitted for at least 5 days or so until they are\u00a0psychiatrically\u00a0stabilized."}
{"id": "article-131342_28", "title": "Substance Use Disorder (Archived) -- History and Physical", "content": "Substance Use History Questions:", "contents": "Substance Use Disorder (Archived) -- History and Physical. Substance Use History Questions:"}
{"id": "article-131342_29", "title": "Substance Use Disorder (Archived) -- History and Physical", "content": "At what age did the individual initiate use of the substance ? This question is asked\u00a0because\u00a0substance use affects\u00a0brain development and\u00a0can\u00a0influence impulsive/risky behaviors from an early age.\u00a0Substance use at\u00a0an early age\u00a0can predispose\u00a0people to be cardiac and neurological disorders in adulthood.", "contents": "Substance Use Disorder (Archived) -- History and Physical. At what age did the individual initiate use of the substance ? This question is asked\u00a0because\u00a0substance use affects\u00a0brain development and\u00a0can\u00a0influence impulsive/risky behaviors from an early age.\u00a0Substance use at\u00a0an early age\u00a0can predispose\u00a0people to be cardiac and neurological disorders in adulthood."}
{"id": "article-131342_30", "title": "Substance Use Disorder (Archived) -- History and Physical", "content": "What benefit is sought out from substance use? Those who use substances may not always use them for recreational use. Some may use it for self-treatment of their co-morbid psychiatric or medical illnesses\u00a0or dealing with stress. For example, those who\u00a0are diagnosed with\u00a0ADHD\u00a0may use Cocaine or Methamphetamine\u00a0as an aid to\u00a0focus.\u00a0Some\u00a0may use Cannabis to treat their anxiety, insomnia,\u00a0or neuropathic pain.\u00a0Therefore,\u00a0it is\u00a0important to be aware of what is the motivation behind substance use.", "contents": "Substance Use Disorder (Archived) -- History and Physical. What benefit is sought out from substance use? Those who use substances may not always use them for recreational use. Some may use it for self-treatment of their co-morbid psychiatric or medical illnesses\u00a0or dealing with stress. For example, those who\u00a0are diagnosed with\u00a0ADHD\u00a0may use Cocaine or Methamphetamine\u00a0as an aid to\u00a0focus.\u00a0Some\u00a0may use Cannabis to treat their anxiety, insomnia,\u00a0or neuropathic pain.\u00a0Therefore,\u00a0it is\u00a0important to be aware of what is the motivation behind substance use."}
{"id": "article-131342_31", "title": "Substance Use Disorder (Archived) -- History and Physical", "content": "Ha s the individual ever attempted to cut back or stop using ?\u00a0This question helps to\u00a0determine\u00a0the motivation for change.\u00a0\u00a0It should be followed up by questions assessing periods of success and potential barriers to implementing strategies to reduce or\u00a0eliminate\u00a0use.", "contents": "Substance Use Disorder (Archived) -- History and Physical. Ha s the individual ever attempted to cut back or stop using ?\u00a0This question helps to\u00a0determine\u00a0the motivation for change.\u00a0\u00a0It should be followed up by questions assessing periods of success and potential barriers to implementing strategies to reduce or\u00a0eliminate\u00a0use."}
{"id": "article-131342_32", "title": "Substance Use Disorder (Archived) -- History and Physical", "content": "Has the patient previously received treatment for a substance use disorder ? Treatment options can include community\u00a0self-help\u00a0groups, outpatient treatment clinics, intensive outpatient programs, medical\u00a0detoxification,\u00a0or\u00a0residential treatment facilities (Rehab)", "contents": "Substance Use Disorder (Archived) -- History and Physical. Has the patient previously received treatment for a substance use disorder ? Treatment options can include community\u00a0self-help\u00a0groups, outpatient treatment clinics, intensive outpatient programs, medical\u00a0detoxification,\u00a0or\u00a0residential treatment facilities (Rehab)"}
{"id": "article-131342_33", "title": "Substance Use Disorder (Archived) -- History and Physical", "content": "Is there a family history of drug use ? If so, have there been any fatalities from substance use? It is\u00a0important to be aware of any substance use by other family members because\u00a0family influences the individual\u2019s risk of substance use.", "contents": "Substance Use Disorder (Archived) -- History and Physical. Is there a family history of drug use ? If so, have there been any fatalities from substance use? It is\u00a0important to be aware of any substance use by other family members because\u00a0family influences the individual\u2019s risk of substance use."}
{"id": "article-131342_34", "title": "Substance Use Disorder (Archived) -- Evaluation", "content": "Evaluation of the patient initially involves approaching the patient in a\u00a0non-judgmental\u00a0manner.\u00a0The provider's diction should concentrate on recovery and goal setting.\u00a0How\u00a0well\u00a0the first interview is conducted sets the tone for\u00a0establishing\u00a0a\u00a0good\u00a0rapport between the provider and patient.\u00a0The provider should always complete the history and physical for assessment.\u00a0Additionally, the healthcare provider should\u00a0obtain a full set of labs\u00a0to help the health provider\u00a0assess the patient\u2019s health.\u00a0The lab tests that are recommended\u00a0include:", "contents": "Substance Use Disorder (Archived) -- Evaluation. Evaluation of the patient initially involves approaching the patient in a\u00a0non-judgmental\u00a0manner.\u00a0The provider's diction should concentrate on recovery and goal setting.\u00a0How\u00a0well\u00a0the first interview is conducted sets the tone for\u00a0establishing\u00a0a\u00a0good\u00a0rapport between the provider and patient.\u00a0The provider should always complete the history and physical for assessment.\u00a0Additionally, the healthcare provider should\u00a0obtain a full set of labs\u00a0to help the health provider\u00a0assess the patient\u2019s health.\u00a0The lab tests that are recommended\u00a0include:"}
{"id": "article-131342_35", "title": "Substance Use Disorder (Archived) -- Evaluation", "content": "Blood Alcohol Level and Urine Drug Screen to screen for acute\u00a0substance use.\u00a0It is\u00a0usually done in the Emergency Room\u00a0if the patient\u00a0exhibits\u00a0agitation,\u00a0sedation,\u00a0or\u00a0cognitive\u00a0impairment.\u00a0Urine\u00a0pregnancy\u00a0tests should also be obtained when\u00a0appropriate. Complete Blood Count\u00a0(CBC)\u00a0may show anemia and infection, while\u00a0Basic Metabolic Panel\u00a0(BMP)\u00a0will show any abnormal electrolyte imbalance\u00a0regarding\u00a0substance use\u00a0and any other co-morbidity. Liver Function Test\u00a0and\u00a0Hepatitis Panel\u00a0can help show any negative effects on the liver from chronic alcohol use\u00a0or other substances; it can also show any hepatitis B\u00a0&\u00a0C\u00a0infections\u00a0from IV drug use.\u00a0HIV antibody test should also be added to rule out any infection from IV drug use. Pancreatic Enzyme's serum level can show any issues with the pancreas from alcohol binge drinking\u00a0or heavy\u00a0nicotine use.", "contents": "Substance Use Disorder (Archived) -- Evaluation. Blood Alcohol Level and Urine Drug Screen to screen for acute\u00a0substance use.\u00a0It is\u00a0usually done in the Emergency Room\u00a0if the patient\u00a0exhibits\u00a0agitation,\u00a0sedation,\u00a0or\u00a0cognitive\u00a0impairment.\u00a0Urine\u00a0pregnancy\u00a0tests should also be obtained when\u00a0appropriate. Complete Blood Count\u00a0(CBC)\u00a0may show anemia and infection, while\u00a0Basic Metabolic Panel\u00a0(BMP)\u00a0will show any abnormal electrolyte imbalance\u00a0regarding\u00a0substance use\u00a0and any other co-morbidity. Liver Function Test\u00a0and\u00a0Hepatitis Panel\u00a0can help show any negative effects on the liver from chronic alcohol use\u00a0or other substances; it can also show any hepatitis B\u00a0&\u00a0C\u00a0infections\u00a0from IV drug use.\u00a0HIV antibody test should also be added to rule out any infection from IV drug use. Pancreatic Enzyme's serum level can show any issues with the pancreas from alcohol binge drinking\u00a0or heavy\u00a0nicotine use."}
{"id": "article-131342_36", "title": "Substance Use Disorder (Archived) -- Evaluation", "content": "For\u00a0establishing\u00a0a\u00a0diagnosis based on substance use, the DSM-5\u00a0is used.\u00a0Per DSM-5, the individual\u00a0must meet at least two criteria out of 11 criteria, over a 12-month period, to have substance use disorder\u00a0established\u00a0for that substance. Overall, the criteria are similar among the substances. PCP Use Disorder does not have a withdrawal criterion\u00a0established, so there are only 10 criteria for that disorder. Some stimulants, opioids, sedatives, anxiolytics, and hypnotics can be used under a physician\u2019s supervision, so tolerance is omitted for individuals taking them for treatment purposes. The 11 problems include:", "contents": "Substance Use Disorder (Archived) -- Evaluation. For\u00a0establishing\u00a0a\u00a0diagnosis based on substance use, the DSM-5\u00a0is used.\u00a0Per DSM-5, the individual\u00a0must meet at least two criteria out of 11 criteria, over a 12-month period, to have substance use disorder\u00a0established\u00a0for that substance. Overall, the criteria are similar among the substances. PCP Use Disorder does not have a withdrawal criterion\u00a0established, so there are only 10 criteria for that disorder. Some stimulants, opioids, sedatives, anxiolytics, and hypnotics can be used under a physician\u2019s supervision, so tolerance is omitted for individuals taking them for treatment purposes. The 11 problems include:"}
{"id": "article-131342_37", "title": "Substance Use Disorder (Archived) -- Evaluation", "content": "The substance use amount is taken more than what was intended and taken longer than what was\u00a0intended.", "contents": "Substance Use Disorder (Archived) -- Evaluation. The substance use amount is taken more than what was intended and taken longer than what was\u00a0intended."}
{"id": "article-131342_38", "title": "Substance Use Disorder (Archived) -- Evaluation", "content": "There is the intention and failed attempts to decrease\u00a0use.", "contents": "Substance Use Disorder (Archived) -- Evaluation. There is the intention and failed attempts to decrease\u00a0use."}
{"id": "article-131342_39", "title": "Substance Use Disorder (Archived) -- Evaluation", "content": "Extra time and effort are used to obtain and use the\u00a0substance or\u00a0recover after taking\u00a0them.", "contents": "Substance Use Disorder (Archived) -- Evaluation. Extra time and effort are used to obtain and use the\u00a0substance or\u00a0recover after taking\u00a0them."}
{"id": "article-131342_40", "title": "Substance Use Disorder (Archived) -- Evaluation", "content": "Having a strong craving for the substance.", "contents": "Substance Use Disorder (Archived) -- Evaluation. Having a strong craving for the substance."}
{"id": "article-131342_41", "title": "Substance Use Disorder (Archived) -- Evaluation", "content": "The use of the substance leads to the individual unable to fulfill his or her responsibility.", "contents": "Substance Use Disorder (Archived) -- Evaluation. The use of the substance leads to the individual unable to fulfill his or her responsibility."}
{"id": "article-131342_42", "title": "Substance Use Disorder (Archived) -- Evaluation", "content": "Continued use of the substance despite having social and occupational impairment due to the substance use.", "contents": "Substance Use Disorder (Archived) -- Evaluation. Continued use of the substance despite having social and occupational impairment due to the substance use."}
{"id": "article-131342_43", "title": "Substance Use Disorder (Archived) -- Evaluation", "content": "Other activities are reduced or given up due to continued substance\u00a0use.", "contents": "Substance Use Disorder (Archived) -- Evaluation. Other activities are reduced or given up due to continued substance\u00a0use."}
{"id": "article-131342_44", "title": "Substance Use Disorder (Archived) -- Evaluation", "content": "Using the substance in a high-risk setting, such as when\u00a0operating\u00a0a motor vehicle or\u00a0operating\u00a0heavy machinery", "contents": "Substance Use Disorder (Archived) -- Evaluation. Using the substance in a high-risk setting, such as when\u00a0operating\u00a0a motor vehicle or\u00a0operating\u00a0heavy machinery"}
{"id": "article-131342_45", "title": "Substance Use Disorder (Archived) -- Evaluation", "content": "Continued use of the substance with the knowledge of the psychological and physical harmful effects caused by the substance.", "contents": "Substance Use Disorder (Archived) -- Evaluation. Continued use of the substance with the knowledge of the psychological and physical harmful effects caused by the substance."}
{"id": "article-131342_46", "title": "Substance Use Disorder (Archived) -- Evaluation", "content": "Tolerance development either from taking more amount of the substance to reach the same effect from last time or from having decreased effect from using the same amount of the substance.", "contents": "Substance Use Disorder (Archived) -- Evaluation. Tolerance development either from taking more amount of the substance to reach the same effect from last time or from having decreased effect from using the same amount of the substance."}
{"id": "article-131342_47", "title": "Substance Use Disorder (Archived) -- Evaluation", "content": "Withdrawal symptoms are manifested after the substance use is\u00a0discontinued, and the withdrawal symptoms are relieved with the continuation of substance use.", "contents": "Substance Use Disorder (Archived) -- Evaluation. Withdrawal symptoms are manifested after the substance use is\u00a0discontinued, and the withdrawal symptoms are relieved with the continuation of substance use."}
{"id": "article-131342_48", "title": "Substance Use Disorder (Archived) -- Evaluation", "content": "The number of\u00a0criteria\u00a0the patient meets\u00a0determines\u00a0the severity level of the disorder; 2-3 sets the severity level as mild, 4-5 sets the severity level as moderate, and 6 or more sets the severity level as severe. A patient can relapse\u00a0after reaching\u00a0remission.\u00a0For the patient to be in\u00a0remission,\u00a0the\u00a0patient must meet at least 2 criteria, which are listed above,\u00a0over a 12-months period,\u00a0and be abstinent from substance use for at least 3 months.\u00a0The\u00a0period of\u00a0time\u00a0from 3-12 months where\u00a0symptoms are in\u00a0remission\u00a0is referred to as early\u00a0full\u00a0remission; after 12 months, the condition is classified as\u00a0sustained\u00a0remission.", "contents": "Substance Use Disorder (Archived) -- Evaluation. The number of\u00a0criteria\u00a0the patient meets\u00a0determines\u00a0the severity level of the disorder; 2-3 sets the severity level as mild, 4-5 sets the severity level as moderate, and 6 or more sets the severity level as severe. A patient can relapse\u00a0after reaching\u00a0remission.\u00a0For the patient to be in\u00a0remission,\u00a0the\u00a0patient must meet at least 2 criteria, which are listed above,\u00a0over a 12-months period,\u00a0and be abstinent from substance use for at least 3 months.\u00a0The\u00a0period of\u00a0time\u00a0from 3-12 months where\u00a0symptoms are in\u00a0remission\u00a0is referred to as early\u00a0full\u00a0remission; after 12 months, the condition is classified as\u00a0sustained\u00a0remission."}
{"id": "article-131342_49", "title": "Substance Use Disorder (Archived) -- Treatment / Management", "content": "Currently, nicotine, alcohol, and opioids are the only substances\u00a0with FDA-approved medication treatments. Individuals with severe addiction may require\u00a0assistance\u00a0in a structured environment for the recovery process. The American Society of Addiction Medicine (ASAM)\u00a0provides\u00a0a\u00a0set of criteria for\u00a0individualized\u00a0treatment planning\u00a0and placement of individuals with addiction. The ASAM criteria involve six\u00a0dimensions:\u00a0intoxication/withdrawal potential, medical condition and history, mental health, individual's\u00a0willingness\u00a0to change, relapse/continue use potential, and recovery/living situation. [21] Patients who\u00a0require\u00a0further\u00a0assistance\u00a0after being discharged from\u00a024-hour inpatient care or\u00a0do not\u00a0qualify for inpatient\u00a0care\u00a0may receive treatment from\u00a0intensive\u00a0outpatient programs (IOPs). IOPs\u00a0do not\u00a0require patients\u00a0to be admitted. Instead, the\u00a0patients\u00a0can stay in\u00a0their\u00a0homes while they are treated in an outpatient\u00a0clinic\u00a0for substance use during the day. IOPs comprise\u00a0psychosocial support, developing coping skills, and any other needed services individually. [22]", "contents": "Substance Use Disorder (Archived) -- Treatment / Management. Currently, nicotine, alcohol, and opioids are the only substances\u00a0with FDA-approved medication treatments. Individuals with severe addiction may require\u00a0assistance\u00a0in a structured environment for the recovery process. The American Society of Addiction Medicine (ASAM)\u00a0provides\u00a0a\u00a0set of criteria for\u00a0individualized\u00a0treatment planning\u00a0and placement of individuals with addiction. The ASAM criteria involve six\u00a0dimensions:\u00a0intoxication/withdrawal potential, medical condition and history, mental health, individual's\u00a0willingness\u00a0to change, relapse/continue use potential, and recovery/living situation. [21] Patients who\u00a0require\u00a0further\u00a0assistance\u00a0after being discharged from\u00a024-hour inpatient care or\u00a0do not\u00a0qualify for inpatient\u00a0care\u00a0may receive treatment from\u00a0intensive\u00a0outpatient programs (IOPs). IOPs\u00a0do not\u00a0require patients\u00a0to be admitted. Instead, the\u00a0patients\u00a0can stay in\u00a0their\u00a0homes while they are treated in an outpatient\u00a0clinic\u00a0for substance use during the day. IOPs comprise\u00a0psychosocial support, developing coping skills, and any other needed services individually. [22]"}
{"id": "article-131342_50", "title": "Substance Use Disorder (Archived) -- Treatment / Management", "content": "To treat nicotine\u00a0use\u00a0disorder, bupropion, varenicline, and nicotine replacement therapy are available.", "contents": "Substance Use Disorder (Archived) -- Treatment / Management. To treat nicotine\u00a0use\u00a0disorder, bupropion, varenicline, and nicotine replacement therapy are available."}
{"id": "article-131342_51", "title": "Substance Use Disorder (Archived) -- Treatment / Management", "content": "Bupropion\u00a0is a dual reuptake inhibitor of\u00a0dopamine and norepinephrine, which helps with nicotine cravings and withdrawal symptoms. [23] Varenicline has a strong affinity to nicotinic acetylcholine\u00a0receptors\u00a0and acts as a partial agonist, reducing withdrawal symptoms and blocking nicotine binding. It\u00a0provides\u00a0the same stimulation as\u00a0nicotine\u00a0and decreases the urge to use nicotine. Also, varenicline does not\u00a0interact with CYP450 enzymes, which can be\u00a0beneficial when treating\u00a0patients with other medications metabolized through the CYP450 pathway. [24] Nicotine\u00a0replacement therapy (NRT) with\u00a0patches and nicotine gum\u00a0help with cravings and withdrawal symptoms. Some studies show a combination of the gum and the patch improves smoking cessation rates. [25] In any\u00a0clinical setting,\u00a0healthcare providers\u00a0should\u00a0provide\u00a0education and resources for smoking cessation, as the health benefits of smoking cessation\u00a0are significant.", "contents": "Substance Use Disorder (Archived) -- Treatment / Management. Bupropion\u00a0is a dual reuptake inhibitor of\u00a0dopamine and norepinephrine, which helps with nicotine cravings and withdrawal symptoms. [23] Varenicline has a strong affinity to nicotinic acetylcholine\u00a0receptors\u00a0and acts as a partial agonist, reducing withdrawal symptoms and blocking nicotine binding. It\u00a0provides\u00a0the same stimulation as\u00a0nicotine\u00a0and decreases the urge to use nicotine. Also, varenicline does not\u00a0interact with CYP450 enzymes, which can be\u00a0beneficial when treating\u00a0patients with other medications metabolized through the CYP450 pathway. [24] Nicotine\u00a0replacement therapy (NRT) with\u00a0patches and nicotine gum\u00a0help with cravings and withdrawal symptoms. Some studies show a combination of the gum and the patch improves smoking cessation rates. [25] In any\u00a0clinical setting,\u00a0healthcare providers\u00a0should\u00a0provide\u00a0education and resources for smoking cessation, as the health benefits of smoking cessation\u00a0are significant."}
{"id": "article-131342_52", "title": "Substance Use Disorder (Archived) -- Treatment / Management", "content": "For stimulant use disorder, such as with cocaine and amphetamine drugs,\u00a0there are no approved pharmacological treatments. [26] However,\u00a0non-pharmacological therapy, such as\u00a0contingency management, is available;\u00a0it\u00a0involves operant conditioning\u00a0reinforcement. The goal of the treatment is to influence a certain type of behavior via behavioral rewards. In substance use, behavior is\u00a0modified\u00a0by\u00a0providing\u00a0a\u00a0reward\u00a0in exchange for the desired behavior, such as\u00a0decrease substance use or abstinence. [27]", "contents": "Substance Use Disorder (Archived) -- Treatment / Management. For stimulant use disorder, such as with cocaine and amphetamine drugs,\u00a0there are no approved pharmacological treatments. [26] However,\u00a0non-pharmacological therapy, such as\u00a0contingency management, is available;\u00a0it\u00a0involves operant conditioning\u00a0reinforcement. The goal of the treatment is to influence a certain type of behavior via behavioral rewards. In substance use, behavior is\u00a0modified\u00a0by\u00a0providing\u00a0a\u00a0reward\u00a0in exchange for the desired behavior, such as\u00a0decrease substance use or abstinence. [27]"}
{"id": "article-131342_53", "title": "Substance Use Disorder (Archived) -- Treatment / Management", "content": "The FDA approves acamprosate, naltrexone, and disulfiram to treat alcohol use disorder. [28] Disulfiram, an aldehyde dehydrogenase inhibitor, produces an unpleasant set of symptoms such as headache, nausea, vomiting, flushing, dizziness, and weakness when alcohol is consumed to\u00a0prevent further alcohol consumption. [29] Naltrexone blocks the central mu-receptor, reducing cravings, and aids in preventing relapse to alcohol use. [30] Acamprosate aids in reducing withdrawal symptoms by countering excessive NMDA receptor activation from alcohol withdrawal. In the clinical setting,\u00a0it is\u00a0important to\u00a0include\u00a0vitamin B1 and vitamin B9, along with multivitamins\u00a0supplements, to address\u00a0any nutritional\u00a0deficiencies.", "contents": "Substance Use Disorder (Archived) -- Treatment / Management. The FDA approves acamprosate, naltrexone, and disulfiram to treat alcohol use disorder. [28] Disulfiram, an aldehyde dehydrogenase inhibitor, produces an unpleasant set of symptoms such as headache, nausea, vomiting, flushing, dizziness, and weakness when alcohol is consumed to\u00a0prevent further alcohol consumption. [29] Naltrexone blocks the central mu-receptor, reducing cravings, and aids in preventing relapse to alcohol use. [30] Acamprosate aids in reducing withdrawal symptoms by countering excessive NMDA receptor activation from alcohol withdrawal. In the clinical setting,\u00a0it is\u00a0important to\u00a0include\u00a0vitamin B1 and vitamin B9, along with multivitamins\u00a0supplements, to address\u00a0any nutritional\u00a0deficiencies."}
{"id": "article-131342_54", "title": "Substance Use Disorder (Archived) -- Treatment / Management", "content": "For\u00a0opioid\u00a0use\u00a0disorder,\u00a0several treatment options are available. They\u00a0include\u00a0methadone, naltrexone, and buprenorphine, which are\u00a0frequently\u00a0combined with naloxone to reduce the risk of\u00a0misuse. Methadone (full\u00a0mu\u00a0agonist)\u00a0can only be\u00a0used to treat opioid use disorder by specific treatment facilities\u00a0designated\u00a0as Opioid Treatment Programs (OTPs). Methadone has decades of research\u00a0demonstrated\u00a0reduced\u00a0illegal drug use, criminal activity,\u00a0mortality, and morbidity, buprenorphine-naloxone (partial agonist at the mu-opioid receptor). As a partial agonist,\u00a0this\u00a0agent\u00a0has\u00a0less potential for\u00a0overdose. [14] During opioid withdrawal, the patient\u00a0can experience dysregulated mood, dyssomnia, pupillary\u00a0dilation, muscle pain, nausea, vomiting, excessive lacrimation, and other symptoms. The (Clinical Opiate Withdrawal Scale) COWS scale is an 11-item rating system used to measure the severity of opioid withdrawal; a score of 5 or above\u00a0indicates active\u00a0withdrawal. Clonidine, an alpha-2 receptor agonist, may help reduce the severity of withdrawal symptoms and stabilize blood pressure. Loperamide may also be needed to aid the patient's GI effect in the setting of repeated diarrhea during withdrawal. [31]", "contents": "Substance Use Disorder (Archived) -- Treatment / Management. For\u00a0opioid\u00a0use\u00a0disorder,\u00a0several treatment options are available. They\u00a0include\u00a0methadone, naltrexone, and buprenorphine, which are\u00a0frequently\u00a0combined with naloxone to reduce the risk of\u00a0misuse. Methadone (full\u00a0mu\u00a0agonist)\u00a0can only be\u00a0used to treat opioid use disorder by specific treatment facilities\u00a0designated\u00a0as Opioid Treatment Programs (OTPs). Methadone has decades of research\u00a0demonstrated\u00a0reduced\u00a0illegal drug use, criminal activity,\u00a0mortality, and morbidity, buprenorphine-naloxone (partial agonist at the mu-opioid receptor). As a partial agonist,\u00a0this\u00a0agent\u00a0has\u00a0less potential for\u00a0overdose. [14] During opioid withdrawal, the patient\u00a0can experience dysregulated mood, dyssomnia, pupillary\u00a0dilation, muscle pain, nausea, vomiting, excessive lacrimation, and other symptoms. The (Clinical Opiate Withdrawal Scale) COWS scale is an 11-item rating system used to measure the severity of opioid withdrawal; a score of 5 or above\u00a0indicates active\u00a0withdrawal. Clonidine, an alpha-2 receptor agonist, may help reduce the severity of withdrawal symptoms and stabilize blood pressure. Loperamide may also be needed to aid the patient's GI effect in the setting of repeated diarrhea during withdrawal. [31]"}
{"id": "article-131342_55", "title": "Substance Use Disorder (Archived) -- Treatment / Management -- Mainstreaming Addiction Treatment (MAT) Act", "content": "The Mainstreaming Addiction Treatment (MAT) Act provision updates federal guidelines to expand the availability of evidence-based treatment to address the opioid epidemic. The MAT Act empowers all health care providers with a standard controlled substance license to p escribe buprenorphine for opioid use disorder (OUD), just as they prescribe other essential medications. The MAT Act is intended to help destigmatize a standard of care for OUD and will integrate substance use disorder treatment across healthcare settings.", "contents": "Substance Use Disorder (Archived) -- Treatment / Management -- Mainstreaming Addiction Treatment (MAT) Act. The Mainstreaming Addiction Treatment (MAT) Act provision updates federal guidelines to expand the availability of evidence-based treatment to address the opioid epidemic. The MAT Act empowers all health care providers with a standard controlled substance license to p escribe buprenorphine for opioid use disorder (OUD), just as they prescribe other essential medications. The MAT Act is intended to help destigmatize a standard of care for OUD and will integrate substance use disorder treatment across healthcare settings."}
{"id": "article-131342_56", "title": "Substance Use Disorder (Archived) -- Treatment / Management -- Mainstreaming Addiction Treatment (MAT) Act", "content": "As of December 2022, the MAT Act has eliminated the DATA-Waiver (X-Waiver) program. All DEA-registered practitioners with Schedule III authority may now prescribe buprenorphine for OUD in their practice if permitted by applicable state law, and SAMHSA encourages them to do so. Prescribers who were registered as DATA-Waiver prescribers will receive a new DEA registration certificate reflecting this change; no action is needed on the part of registrants.", "contents": "Substance Use Disorder (Archived) -- Treatment / Management -- Mainstreaming Addiction Treatment (MAT) Act. As of December 2022, the MAT Act has eliminated the DATA-Waiver (X-Waiver) program. All DEA-registered practitioners with Schedule III authority may now prescribe buprenorphine for OUD in their practice if permitted by applicable state law, and SAMHSA encourages them to do so. Prescribers who were registered as DATA-Waiver prescribers will receive a new DEA registration certificate reflecting this change; no action is needed on the part of registrants."}
{"id": "article-131342_57", "title": "Substance Use Disorder (Archived) -- Treatment / Management -- Mainstreaming Addiction Treatment (MAT) Act", "content": "There are no longer any limits on the number of patients with OUD that a practitioner may treat with buprenorphine. Separate tracking of patients treated with buprenorphine or prescriptions written is no longer required.", "contents": "Substance Use Disorder (Archived) -- Treatment / Management -- Mainstreaming Addiction Treatment (MAT) Act. There are no longer any limits on the number of patients with OUD that a practitioner may treat with buprenorphine. Separate tracking of patients treated with buprenorphine or prescriptions written is no longer required."}
{"id": "article-131342_58", "title": "Substance Use Disorder (Archived) -- Treatment / Management -- Mainstreaming Addiction Treatment (MAT) Act", "content": "Pharmacy staff can now fill buprenorphine prescriptions using the prescribing authority's DEA number and does not need a DATA 2000 waiver from the prescriber. However, depending on the pharmacy, the dispensing software may still require the X-Waiver information in order to proceed. Practitioners are still required to comply with any applicable state limits regarding the treatment of patients with OUD. Contact information for State Opioid Treatment Authorities can be found here:\u00a0https://www.samhsa.gov/medicationassisted-treatment/sota.", "contents": "Substance Use Disorder (Archived) -- Treatment / Management -- Mainstreaming Addiction Treatment (MAT) Act. Pharmacy staff can now fill buprenorphine prescriptions using the prescribing authority's DEA number and does not need a DATA 2000 waiver from the prescriber. However, depending on the pharmacy, the dispensing software may still require the X-Waiver information in order to proceed. Practitioners are still required to comply with any applicable state limits regarding the treatment of patients with OUD. Contact information for State Opioid Treatment Authorities can be found here:\u00a0https://www.samhsa.gov/medicationassisted-treatment/sota."}
{"id": "article-131342_59", "title": "Substance Use Disorder (Archived) -- Differential Diagnosis", "content": "Depression can be\u00a0exhibited\u00a0from opioids, alcohol, sedative, anxiolytic, hypnotic, and cannabis\u00a0use.\u00a0It is also associated with withdrawal from\u00a0stimulants. Mania\u00a0and anxiety can be\u00a0exhibited\u00a0from stimulants\u00a0(cocaine and amphetamine). Psychosis can be\u00a0associated with substances but varies from individual to individual and with time.", "contents": "Substance Use Disorder (Archived) -- Differential Diagnosis. Depression can be\u00a0exhibited\u00a0from opioids, alcohol, sedative, anxiolytic, hypnotic, and cannabis\u00a0use.\u00a0It is also associated with withdrawal from\u00a0stimulants. Mania\u00a0and anxiety can be\u00a0exhibited\u00a0from stimulants\u00a0(cocaine and amphetamine). Psychosis can be\u00a0associated with substances but varies from individual to individual and with time."}
{"id": "article-131342_60", "title": "Substance Use Disorder (Archived) -- Toxicity and Adverse Effect Management", "content": "Patients who are\u00a0physically dependent on sedative effects often require medication during the\u00a0detoxification\u00a0process to minimize the risks associated with complicated withdrawal. Acute intoxication can present with\u00a0slurred speech, cognitive impairment, poor coordination, and unsteady\u00a0gait.\u00a0For\u00a0alcohol\u00a0and benzodiazepine\u00a0withdrawal,\u00a0the\u00a0Clinical Institute Withdrawal Assessment (CIWA)\u00a0scale\u00a0helps\u00a0determine the frequency of medication dosing to prevent withdrawal complications.\u00a0In an emergency setting, treatment for alcohol\u00a0and benzodiazepine\u00a0intoxication is primarily supportive, with close monitoring of\u00a0vitals.\u00a0Benzodiazepines are considered a first-line treatment to prevent worsening withdrawal symptoms. [32] In cases of severe benzodiazepine intoxication, particularly if the patient is becoming hypoxic, flumazenil\u00a0may be indicated.\u00a0Flumazenil reduces the\u00a0expression of GABA\u00a0subunit\u00a0receptors,\u00a0reversing\u00a0the effect of benzodiazepines. [33]", "contents": "Substance Use Disorder (Archived) -- Toxicity and Adverse Effect Management. Patients who are\u00a0physically dependent on sedative effects often require medication during the\u00a0detoxification\u00a0process to minimize the risks associated with complicated withdrawal. Acute intoxication can present with\u00a0slurred speech, cognitive impairment, poor coordination, and unsteady\u00a0gait.\u00a0For\u00a0alcohol\u00a0and benzodiazepine\u00a0withdrawal,\u00a0the\u00a0Clinical Institute Withdrawal Assessment (CIWA)\u00a0scale\u00a0helps\u00a0determine the frequency of medication dosing to prevent withdrawal complications.\u00a0In an emergency setting, treatment for alcohol\u00a0and benzodiazepine\u00a0intoxication is primarily supportive, with close monitoring of\u00a0vitals.\u00a0Benzodiazepines are considered a first-line treatment to prevent worsening withdrawal symptoms. [32] In cases of severe benzodiazepine intoxication, particularly if the patient is becoming hypoxic, flumazenil\u00a0may be indicated.\u00a0Flumazenil reduces the\u00a0expression of GABA\u00a0subunit\u00a0receptors,\u00a0reversing\u00a0the effect of benzodiazepines. [33]"}
{"id": "article-131342_61", "title": "Substance Use Disorder (Archived) -- Toxicity and Adverse Effect Management", "content": "For opioid intoxication,\u00a0naloxone is used\u00a0to reverse respiratory depression\u00a0caused by opioid overdose.\u00a0Naloxone is a competitive mu-opioid receptor antagonist, which reverses the effects of opioids.\u00a0It can be administered intramuscularly, intravenously, or\u00a0nasally; the fastest route of administration is intravenous. [34]", "contents": "Substance Use Disorder (Archived) -- Toxicity and Adverse Effect Management. For opioid intoxication,\u00a0naloxone is used\u00a0to reverse respiratory depression\u00a0caused by opioid overdose.\u00a0Naloxone is a competitive mu-opioid receptor antagonist, which reverses the effects of opioids.\u00a0It can be administered intramuscularly, intravenously, or\u00a0nasally; the fastest route of administration is intravenous. [34]"}
{"id": "article-131342_62", "title": "Substance Use Disorder (Archived) -- Toxicity and Adverse Effect Management", "content": "For PCP intoxication, the\u00a0focus\u00a0is stabilizing the patient with supportive care.\u00a0The patient\u00a0may exhibit\u00a0ataxia, nystagmus, increase cardiac workload, muscle\u00a0rigidity,\u00a0and seizures.\u00a0Hyperacusis is another side-effect of PCP use, which is why it may be necessary to place the patient in a low stimulus environment. A high stimulus\u00a0environment may trigger\u00a0agitation\u00a0and increase the likelihood that\u00a0restraints are required. In some cases, gastric\u00a0suction\u00a0or the use of activated charcoal may be indicated. Benzodiazepines\u00a0may\u00a0help to control agitation and reduce the risk of seizures. [19]", "contents": "Substance Use Disorder (Archived) -- Toxicity and Adverse Effect Management. For PCP intoxication, the\u00a0focus\u00a0is stabilizing the patient with supportive care.\u00a0The patient\u00a0may exhibit\u00a0ataxia, nystagmus, increase cardiac workload, muscle\u00a0rigidity,\u00a0and seizures.\u00a0Hyperacusis is another side-effect of PCP use, which is why it may be necessary to place the patient in a low stimulus environment. A high stimulus\u00a0environment may trigger\u00a0agitation\u00a0and increase the likelihood that\u00a0restraints are required. In some cases, gastric\u00a0suction\u00a0or the use of activated charcoal may be indicated. Benzodiazepines\u00a0may\u00a0help to control agitation and reduce the risk of seizures. [19]"}
{"id": "article-131342_63", "title": "Substance Use Disorder (Archived) -- Staging", "content": "During the\u00a0recovery process\u00a0of substance use, the individual transitions through\u00a0various stages\u00a0of change, demonstrated\u00a0as the stages of change model. Precontemplation,\u00a0when the individual does not recognize the negative effects of substance use. Contemplation,\u00a0when the issues of substance use are recognized, yet\u00a0no action is taken. Preparation, when the individual has considered making a change\u00a0regarding\u00a0substance\u00a0use and\u00a0begins to make minor changes. Action\u00a0is the\u00a0stage when the individual makes significant changes to prevent substance use, such as avoiding triggers or reaching out for help. Maintenance, the stage when the action stage is\u00a0maintained\u00a0to\u00a0prevent substance use. Relapse, the stage when the substance use is\u00a0restarted. [35]", "contents": "Substance Use Disorder (Archived) -- Staging. During the\u00a0recovery process\u00a0of substance use, the individual transitions through\u00a0various stages\u00a0of change, demonstrated\u00a0as the stages of change model. Precontemplation,\u00a0when the individual does not recognize the negative effects of substance use. Contemplation,\u00a0when the issues of substance use are recognized, yet\u00a0no action is taken. Preparation, when the individual has considered making a change\u00a0regarding\u00a0substance\u00a0use and\u00a0begins to make minor changes. Action\u00a0is the\u00a0stage when the individual makes significant changes to prevent substance use, such as avoiding triggers or reaching out for help. Maintenance, the stage when the action stage is\u00a0maintained\u00a0to\u00a0prevent substance use. Relapse, the stage when the substance use is\u00a0restarted. [35]"}
{"id": "article-131342_64", "title": "Substance Use Disorder (Archived) -- Prognosis", "content": "Individuals who abuse\u00a0substances\u00a0for\u00a0a chronic period\u00a0develop extreme dependence\u00a0on them. If the\u00a0individual\u00a0attempts to stop using\u00a0it, their withdrawal symptoms\u00a0become\u00a0severe enough for the individual to\u00a0restart the abuse cycle.\u00a0There are predicting factors that influence the outcome for the individual; the degree of relationship between the predictor factor and the outcome varies\u00a0from\u00a0person to person.\u00a0Some of the predicting\u00a0factors include but not limited to are the degree of dependence and withdrawal, the motivation to be committed to abstinence, treatment timeframe, genetics, the severity of cravings, and how the individual copes during stressful situations. [36]", "contents": "Substance Use Disorder (Archived) -- Prognosis. Individuals who abuse\u00a0substances\u00a0for\u00a0a chronic period\u00a0develop extreme dependence\u00a0on them. If the\u00a0individual\u00a0attempts to stop using\u00a0it, their withdrawal symptoms\u00a0become\u00a0severe enough for the individual to\u00a0restart the abuse cycle.\u00a0There are predicting factors that influence the outcome for the individual; the degree of relationship between the predictor factor and the outcome varies\u00a0from\u00a0person to person.\u00a0Some of the predicting\u00a0factors include but not limited to are the degree of dependence and withdrawal, the motivation to be committed to abstinence, treatment timeframe, genetics, the severity of cravings, and how the individual copes during stressful situations. [36]"}
{"id": "article-131342_65", "title": "Substance Use Disorder (Archived) -- Complications", "content": "The complications of substance use\u00a0are\u00a0broad.", "contents": "Substance Use Disorder (Archived) -- Complications. The complications of substance use\u00a0are\u00a0broad."}
{"id": "article-131342_66", "title": "Substance Use Disorder (Archived) -- Complications", "content": "Substance use will impact\u00a0multiple systems of the body, including but not limited to neurologic,\u00a0endocrine,\u00a0psychiatric,\u00a0cardiopulmonary, hepatic,\u00a0hematologic, and\u00a0immunologic.\u00a0These problems include\u00a0but not limited to are: Stroke\u00a0and seizures Loss of nerve functions leading to muscle weakness and loss of\u00a0sensation. Memory\u00a0loss and overall\u00a0cognitive deficits. Various forms of psychosis,\u00a0loss of impulse control,\u00a0personality change,\u00a0and\u00a0mood dysregulation. Coma and death Increased cardiac workload and with chronic use cardiac\u00a0failure. Nasal Septal Perforation Respiratory depression Muscle breakdown from overuse, leading to\u00a0rhabdomyolysis. Liver failure and hepatocellular carcinoma Hepatitis B & C infections, HIV, sepsis, and gangrene", "contents": "Substance Use Disorder (Archived) -- Complications. Substance use will impact\u00a0multiple systems of the body, including but not limited to neurologic,\u00a0endocrine,\u00a0psychiatric,\u00a0cardiopulmonary, hepatic,\u00a0hematologic, and\u00a0immunologic.\u00a0These problems include\u00a0but not limited to are: Stroke\u00a0and seizures Loss of nerve functions leading to muscle weakness and loss of\u00a0sensation. Memory\u00a0loss and overall\u00a0cognitive deficits. Various forms of psychosis,\u00a0loss of impulse control,\u00a0personality change,\u00a0and\u00a0mood dysregulation. Coma and death Increased cardiac workload and with chronic use cardiac\u00a0failure. Nasal Septal Perforation Respiratory depression Muscle breakdown from overuse, leading to\u00a0rhabdomyolysis. Liver failure and hepatocellular carcinoma Hepatitis B & C infections, HIV, sepsis, and gangrene"}
{"id": "article-131342_67", "title": "Substance Use Disorder (Archived) -- Deterrence and Patient Education", "content": "Substance use frequently starts at\u00a0an early age, so education of the general population starting in school can reduce the prevalence of substance\u00a0use disorders.\u00a0 Identifying high-risk patient populations and reducing care barriers can help limit the negative impact of substance use disorders.", "contents": "Substance Use Disorder (Archived) -- Deterrence and Patient Education. Substance use frequently starts at\u00a0an early age, so education of the general population starting in school can reduce the prevalence of substance\u00a0use disorders.\u00a0 Identifying high-risk patient populations and reducing care barriers can help limit the negative impact of substance use disorders."}
{"id": "article-131342_68", "title": "Substance Use Disorder (Archived) -- Enhancing Healthcare Team Outcomes", "content": "Effective\u00a0education\u00a0on the treatment of substance use disorders among\u00a0healthcare providers\u00a0can help\u00a0to improve outcomes.\u00a0Unfortunately,\u00a0training in substance-related/addictive disorders is frequently limited, leaving providers ill-equipped to meet the demand after training. Additionally, a\u00a0lack of adequate curriculum\u00a0for healthcare provider training\u00a0and a negative view of patients with substance use disorders plays a role\u00a0in poor\u00a0healthcare\u00a0outcomes. [37]", "contents": "Substance Use Disorder (Archived) -- Enhancing Healthcare Team Outcomes. Effective\u00a0education\u00a0on the treatment of substance use disorders among\u00a0healthcare providers\u00a0can help\u00a0to improve outcomes.\u00a0Unfortunately,\u00a0training in substance-related/addictive disorders is frequently limited, leaving providers ill-equipped to meet the demand after training. Additionally, a\u00a0lack of adequate curriculum\u00a0for healthcare provider training\u00a0and a negative view of patients with substance use disorders plays a role\u00a0in poor\u00a0healthcare\u00a0outcomes. [37]"}
{"id": "article-131342_69", "title": "Substance Use Disorder (Archived) -- Enhancing Healthcare Team Outcomes", "content": "Unless\u00a0emergency\u00a0treatment\u00a0requires it, prescribing potentially addictive\u00a0medications should\u00a0be\u00a0limited\u00a0to\u00a0healthcare\u00a0providers specifically\u00a0trained in substance-related/addictive disorders. When utilizing medications in the treatment of substance use disorders, healthcare providers should not place arbitrary limits on treatment duration. All treatment decisions should be patient-centered and based on the\u00a0unique risk/benefit analysis.\u00a0 The American Academy of Addiction Psychiatry (AAAP), along with the Substance Abuse and Mental Health Services Administration (SAMHSA), sponsors\u00a0Providers Clinical Support System\u00a0(PCSS), a\u00a0training\u00a0program\u00a0for physicians and other healthcare providers. This program offers training, mentorship, and other support for individuals interested in preventing, identifying, and treating opioid use disorders.", "contents": "Substance Use Disorder (Archived) -- Enhancing Healthcare Team Outcomes. Unless\u00a0emergency\u00a0treatment\u00a0requires it, prescribing potentially addictive\u00a0medications should\u00a0be\u00a0limited\u00a0to\u00a0healthcare\u00a0providers specifically\u00a0trained in substance-related/addictive disorders. When utilizing medications in the treatment of substance use disorders, healthcare providers should not place arbitrary limits on treatment duration. All treatment decisions should be patient-centered and based on the\u00a0unique risk/benefit analysis.\u00a0 The American Academy of Addiction Psychiatry (AAAP), along with the Substance Abuse and Mental Health Services Administration (SAMHSA), sponsors\u00a0Providers Clinical Support System\u00a0(PCSS), a\u00a0training\u00a0program\u00a0for physicians and other healthcare providers. This program offers training, mentorship, and other support for individuals interested in preventing, identifying, and treating opioid use disorders."}
{"id": "article-131342_70", "title": "Substance Use Disorder (Archived) -- Enhancing Healthcare Team Outcomes", "content": "Dealing with substance use disorder requires the efforts of all members of the interprofessional healthcare team, including clinicians, mid-level practitioners, nursing staff, and pharmacists, who can coordinate their activities and engage in open communication to help identify substance use disorder, streamline treatment, and watch for signs of relapse once therapy has been initiated. This interprofessional approach stands the best chance of patient success in recovering from substance use disorder. [Level 5]", "contents": "Substance Use Disorder (Archived) -- Enhancing Healthcare Team Outcomes. Dealing with substance use disorder requires the efforts of all members of the interprofessional healthcare team, including clinicians, mid-level practitioners, nursing staff, and pharmacists, who can coordinate their activities and engage in open communication to help identify substance use disorder, streamline treatment, and watch for signs of relapse once therapy has been initiated. This interprofessional approach stands the best chance of patient success in recovering from substance use disorder. [Level 5]"}
{"id": "article-131342_71", "title": "Substance Use Disorder (Archived) -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Substance Use Disorder (Archived) -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}